Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study
- PMID: 3978246
- DOI: 10.1007/BF01807642
Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study
Abstract
Eleven surgical pathologists studied microscopic sections from 45 mastectomy specimens of node positive breast cancer patients who had been entered into ECOG clinical trials. Inter-observer reproducibility for histoprognostic features was examined as a prerequisite before a subsequent evaluation of their possible clinical applicability could be undertaken. Histological type, nuclear grade, tubular formation, and lymphoid reactions were studied in the cancerous tissues. Lymph nodal responses (follicular and pulp prominence, sinus histiocytosis) were also examined in a manner that stimulated slide review in routine surgical pathology practice. Numerous two-way comparisons of the pathologists' findings resulted in low levels of agreement (usually much less than 90%). The degree of inter-observer reliability is clinically unacceptable using customary slide review analysis. New ways of examining breast cancer tissues need to be explored in the search for prognostic features which can be applied to the clinical management of breast cancer patients.
Similar articles
-
The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer. The Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section.Jpn J Clin Oncol. 1999 Feb;29(2):68-73. doi: 10.1093/jjco/29.2.68. Jpn J Clin Oncol. 1999. PMID: 10089946
-
Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial interobserver concordance.Histopathology. 2018 Dec;73(6):923-932. doi: 10.1111/his.13741. Epub 2018 Oct 22. Histopathology. 2018. PMID: 30168167
-
Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section.Jpn J Clin Oncol. 1998 Aug;28(8):486-91. doi: 10.1093/jjco/28.8.486. Jpn J Clin Oncol. 1998. PMID: 9769782 Clinical Trial.
-
Management of axillary disease.Surg Oncol Clin N Am. 2014 Jul;23(3):473-86. doi: 10.1016/j.soc.2014.03.007. Epub 2014 Apr 13. Surg Oncol Clin N Am. 2014. PMID: 24882346 Review.
-
FDG-PET for axillary lymph node staging in primary breast cancer.Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S97-102. doi: 10.1007/s00259-004-1531-z. Epub 2004 May 5. Eur J Nucl Med Mol Imaging. 2004. PMID: 15133635 Review.
Cited by
-
Immunohistochemical reaction to human milk fat globule antibodies and breast cancer differentiation.Breast Cancer Res Treat. 1992;23(1-2):71-6. doi: 10.1007/BF01831478. Breast Cancer Res Treat. 1992. PMID: 1446055
-
The Nottingham Prognostic Index in primary breast cancer.Breast Cancer Res Treat. 1992;22(3):207-19. doi: 10.1007/BF01840834. Breast Cancer Res Treat. 1992. PMID: 1391987
-
Vimentin expression in 98 breast cancers with medullary features and its prognostic significance.Virchows Arch A Pathol Anat Histopathol. 1993;422(6):475-9. doi: 10.1007/BF01606456. Virchows Arch A Pathol Anat Histopathol. 1993. PMID: 8392769
-
Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues.Breast Cancer Res. 2015 Aug 20;17(1):105. doi: 10.1186/s13058-015-0617-9. Breast Cancer Res. 2015. PMID: 26290094 Free PMC article.
-
AI-enabled routine H&E image based prognostic marker for early-stage luminal breast cancer.NPJ Precis Oncol. 2023 Nov 15;7(1):122. doi: 10.1038/s41698-023-00472-y. NPJ Precis Oncol. 2023. PMID: 37968376 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Medical